Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript Summary
Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript Summary
G&A expenses decreased to $5.2 million, down from $9.3 million due to a one-time non-cash expense related to historical grants recognized in 2023.The following is a summary of the Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript:
以下是chimerix公司（CMRX）2024年第三季度業績會交易摘要：
Financial Performance:
財務表現:
Chimerix reported a net loss of $22.9 million for Q3 2024, an improvement from a net loss of $24 million in Q3 2023.
R&D expenses increased to $19.6 million, primarily due to spending in the ACTION study.
G&A expenses decreased to $5.2 million, down from $9.3 million due to a one-time non-cash expense related to historical grants recognized in 2023.
Chimerix ended the quarter with $152 million in cash and cash equivalents, maintaining a cash runway into Q4 2026.
Chimerix報告了2024年第三季度淨損失達2290萬美元，相比於2023年第三季度的淨損失2400萬美元有所改善。
研發支出增加至1960萬美元，主要是因爲在ACTION研究中的支出增加。
總務及行政支出降至520萬美元，比930萬美元減少，這是由於2023年確認的與歷史授予相關的一次性非現金費用。
Chimerix季末現金及現金等價物達15200萬美元，保持現金儲備直至2026年第四季度。
Business Progress:
業務進展:
Phase 3 ACTION study of Dordaviprone nearing complete enrollment; interim results expected within a year.
Positive interim safety review from the independent Data Monitoring Committee for ACTION study.
Plans to file an NDA for provisional approval in Australia by year-end, with a potential U.S. launch following.
Preparations underway for potential commercialization of Dordaviprone, anticipating significant market uptake.
Phase 1 dose escalation studies for ONC206 nearing completion with next steps to be announced soon.
多達維普隆的第三階段ACTION研究即將完成招募；預計將在一年內公佈中期結果。
獨立數據監測委員會對ACTION研究進行了積極的中期安全審查。
計劃年底前在澳洲提交臨時批准申請，並在之後可能在美國推出。
正在爲Dordaviprone潛在的商業化做準備，預計市場接受度較高。
ONC206的第1階段劑量遞增研究即將完成，下一步計劃將很快公佈。
Opportunities:
機會：
Anticipated rapid uptake and significant market opportunity for Dordaviprone, with a potential global market over $750 million.
Dordaviprone預期快速接受和巨大市場機會，全球市場潛在超過75000萬美元。
Risks:
風險：
The global Phase 3 ACTION study's success is pivotal for future regulatory approvals and Dordaviprone's market potential.
全球第3階段ACTION研究的成功對未來的監管批准和Dordaviprone的市場潛力至關重要。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
